Cargando…

Development of a novel plaque reduction neutralisation test for hantavirus infection

In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for...

Descripción completa

Detalles Bibliográficos
Autores principales: de Pádua, Michelly, de Souza, William Marciel, Lauretti, Flávio, Figueiredo, Luiz Tadeu Moraes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Oswaldo Cruz, Ministério da Saúde 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569825/
https://www.ncbi.nlm.nih.gov/pubmed/26132430
http://dx.doi.org/10.1590/0074-02760150102
_version_ 1782390111831326720
author de Pádua, Michelly
de Souza, William Marciel
Lauretti, Flávio
Figueiredo, Luiz Tadeu Moraes
author_facet de Pádua, Michelly
de Souza, William Marciel
Lauretti, Flávio
Figueiredo, Luiz Tadeu Moraes
author_sort de Pádua, Michelly
collection PubMed
description In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for detecting antibodies to Brazilian hantavirus. Using PRNT, plaque detection was enhanced by adding 0.6% of dimethyl sulfoxide into the overlay culture medium of the infected cells. This procedure facilitated clear visualisation of small plaques under the microscope and provided for easy and accurate plaque counting. The sera from 37 HCPS patients from the city of Ribeirão Preto, Brazil was evaluated for the Rio Mamoré virus (RIOMV) using PRNT. Six samples exhibited neutralising antibodies; these antibodies exhibited a low titre. The low level of seropositive samples may be due to fewer cross-reactions between two different hantavirus species; the patients were likely infected by Araraquara virus (a virus that has not been isolated) and RIOMV was used for the test. This assay offers a new approach to evaluating and measuring neutralising antibodies produced during hantavirus infections and it can be adapted to other hantaviruses, including viruses that will be isolated in the future.
format Online
Article
Text
id pubmed-4569825
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Instituto Oswaldo Cruz, Ministério da Saúde
record_format MEDLINE/PubMed
spelling pubmed-45698252015-09-15 Development of a novel plaque reduction neutralisation test for hantavirus infection de Pádua, Michelly de Souza, William Marciel Lauretti, Flávio Figueiredo, Luiz Tadeu Moraes Mem Inst Oswaldo Cruz Articles In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for detecting antibodies to Brazilian hantavirus. Using PRNT, plaque detection was enhanced by adding 0.6% of dimethyl sulfoxide into the overlay culture medium of the infected cells. This procedure facilitated clear visualisation of small plaques under the microscope and provided for easy and accurate plaque counting. The sera from 37 HCPS patients from the city of Ribeirão Preto, Brazil was evaluated for the Rio Mamoré virus (RIOMV) using PRNT. Six samples exhibited neutralising antibodies; these antibodies exhibited a low titre. The low level of seropositive samples may be due to fewer cross-reactions between two different hantavirus species; the patients were likely infected by Araraquara virus (a virus that has not been isolated) and RIOMV was used for the test. This assay offers a new approach to evaluating and measuring neutralising antibodies produced during hantavirus infections and it can be adapted to other hantaviruses, including viruses that will be isolated in the future. Instituto Oswaldo Cruz, Ministério da Saúde 2015-08 /pmc/articles/PMC4569825/ /pubmed/26132430 http://dx.doi.org/10.1590/0074-02760150102 Text en http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
de Pádua, Michelly
de Souza, William Marciel
Lauretti, Flávio
Figueiredo, Luiz Tadeu Moraes
Development of a novel plaque reduction neutralisation test for hantavirus infection
title Development of a novel plaque reduction neutralisation test for hantavirus infection
title_full Development of a novel plaque reduction neutralisation test for hantavirus infection
title_fullStr Development of a novel plaque reduction neutralisation test for hantavirus infection
title_full_unstemmed Development of a novel plaque reduction neutralisation test for hantavirus infection
title_short Development of a novel plaque reduction neutralisation test for hantavirus infection
title_sort development of a novel plaque reduction neutralisation test for hantavirus infection
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569825/
https://www.ncbi.nlm.nih.gov/pubmed/26132430
http://dx.doi.org/10.1590/0074-02760150102
work_keys_str_mv AT depaduamichelly developmentofanovelplaquereductionneutralisationtestforhantavirusinfection
AT desouzawilliammarciel developmentofanovelplaquereductionneutralisationtestforhantavirusinfection
AT laurettiflavio developmentofanovelplaquereductionneutralisationtestforhantavirusinfection
AT figueiredoluiztadeumoraes developmentofanovelplaquereductionneutralisationtestforhantavirusinfection